Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07856264 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease. This retrospective observational study aims to describe changes in low-density lipoprotein cholesterol (LDL-C) levels following the use of PCSK9 inhibitors in adult patients with hyperlipidemia and/or atherosclerotic cardiovascular disease treated at Fundación Santa Fe de Bogotá between 2018 and 2024. The study will also describe patients' clinical characteristics, treatment effectiveness, safety, adherence, and barriers to treatment access. Data will be obtained from medical records, cardiology records, and telephone interviews when needed to complete missing information.
Trial Details
NCT Number NCT07856264
Lead Sponsor Fundación Santa Fe de Bogota
Conditions
(from sponsor)		 Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Related terms Atherosclerosis, Hyperlipidemias
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov